Sarepta Therapeutics | SRPT - Ativo Circulante





Ativo Circulante Alterar Data
Acadia Pharmaceuticals USD 1.06B 14.31M 2025-12
Agios Pharmaceuticals USD 942.05M 91.06M 2025-12
Alnylam Pharmaceuticals USD 4.05B 97.85M 2025-12
Amgen USD 29.06B 1.17B 2025-12
BioCryst Pharmaceuticals USD 404.35M 48.66M 2025-12
Biogen USD 8.97B 37.5M 2025-12
BioMarin Pharmaceutical USD 3.95B 98.95M 2025-12
Capricor Therapeutics USD 322.94M 221.99M 2025-12
Daiichi Sankyo JPY 2.1T 218.5B 2025-12
Eli Lilly USD 55.63B 6.44B 2025-12
Esperion Therapeutics USD 462.57M 102.11M 2025-12
Gilead Sciences USD 19.89B 1.05B 2025-12
Incyte USD 5.02B 746.01M 2025-12
Insmed USD 1.79B 137.6M 2025-12
Ionis Pharmaceuticals USD 2.99B 471.01M 2025-12
Moderna USD 6.54B 54M 2025-12
Nektar Therapeutics USD 266.27M 15.09M 2025-12
Neurocrine Biosciences USD 2.52B 364.3M 2025-12
Novavax USD 978.28M 3.69M 2025-12
Pfizer USD 46.92B 3.22B 2025-09
PTC Therapeutics USD 2.27B 266.14M 2025-12
Regeneron Pharmaceuticals USD 18.02B 41.2M 2025-12
Roche Holding CHF 38.73B 3.03B 2025-12
Sangamo BioSciences USD 49.89M 12.3M 2025-06
Sanofi EUR 30.95B 3.09B 2025-12
Sarepta Therapeutics USD 2.54B 184.37M 2025-12
Tectonic Therapeutic USD 257.36M 15.88M 2025-12
Ultragenyx Pharmaceutical USD 643.21M 76.58M 2025-09
Vertex Pharmaceuticals USD 11.2B 631.4M 2025-12